PE20230464A1 - Union de anticuerpos multiespecificos a bcma - Google Patents

Union de anticuerpos multiespecificos a bcma

Info

Publication number
PE20230464A1
PE20230464A1 PE2022003030A PE2022003030A PE20230464A1 PE 20230464 A1 PE20230464 A1 PE 20230464A1 PE 2022003030 A PE2022003030 A PE 2022003030A PE 2022003030 A PE2022003030 A PE 2022003030A PE 20230464 A1 PE20230464 A1 PE 20230464A1
Authority
PE
Peru
Prior art keywords
sequence
bcma
seq
binding
specific antibodies
Prior art date
Application number
PE2022003030A
Other languages
English (en)
Inventor
Nathan Trinklein
Katherine Harris
Harbani Malik
Ute Schellenberger
Omid Vafa
Aldred Shelley Force
Original Assignee
Teneobio Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Teneobio Inc filed Critical Teneobio Inc
Publication of PE20230464A1 publication Critical patent/PE20230464A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/35—Valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/569—Single domain, e.g. dAb, sdAb, VHH, VNAR or nanobody®
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Abstract

Referida a un anticuerpo multiespecifico que se une a BCMA, que comprende una primera unidad de union que comprende una region variable que comprende: una secuencia de CDR1 que comprende la secuencia de la SEQ ID NO: 1; una secuencia de CDR2 que comprende la secuencia de la SEQ ID NO: 2; y una secuencia de CDR3 que comprende la secuencia de la SEQ ID NO: 3. Tambien esta referida a metodos para preparar tales anticuerpos, composiciones, incluyendo composiciones farmaceuticas, que comprenden tales anticuerpos y su uso para tratar trastornos que se caracterizan por la expresion de BCMA.
PE2022003030A 2020-06-30 2021-06-30 Union de anticuerpos multiespecificos a bcma PE20230464A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063046477P 2020-06-30 2020-06-30
PCT/US2021/039961 WO2022006316A1 (en) 2020-06-30 2021-06-30 Multi-specific antibodies binding to bcma

Publications (1)

Publication Number Publication Date
PE20230464A1 true PE20230464A1 (es) 2023-03-14

Family

ID=77127069

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2022003030A PE20230464A1 (es) 2020-06-30 2021-06-30 Union de anticuerpos multiespecificos a bcma

Country Status (15)

Country Link
US (1) US20230257473A1 (es)
EP (1) EP4171750A1 (es)
JP (1) JP2023532129A (es)
KR (1) KR20230038211A (es)
CN (1) CN116472049A (es)
AU (1) AU2021300179A1 (es)
BR (1) BR112022027101A2 (es)
CA (1) CA3189297A1 (es)
CL (1) CL2022003754A1 (es)
CO (1) CO2023000808A2 (es)
CR (1) CR20220656A (es)
IL (1) IL299027A (es)
MX (1) MX2022016342A (es)
PE (1) PE20230464A1 (es)
WO (1) WO2022006316A1 (es)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN117567624A (zh) 2017-06-20 2024-02-20 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
KR20200104342A (ko) 2017-12-22 2020-09-03 테네오바이오, 인코포레이티드 Cd22에 결합하는 중쇄 항체
AU2020291938A1 (en) 2019-06-14 2022-01-20 Teneobio, Inc. Multispecific heavy chain antibodies binding to CD22 and CD3

Family Cites Families (32)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
IL85035A0 (en) 1987-01-08 1988-06-30 Int Genetic Eng Polynucleotide molecule,a chimeric antibody with specificity for human b cell surface antigen,a process for the preparation and methods utilizing the same
EP0590058B1 (en) 1991-06-14 2003-11-26 Genentech, Inc. HUMANIZED Heregulin ANTIBODy
US6096871A (en) 1995-04-14 2000-08-01 Genentech, Inc. Polypeptides altered to contain an epitope from the Fc region of an IgG molecule for increased half-life
AU728657B2 (en) 1996-03-18 2001-01-18 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
UA74798C2 (uk) 1999-10-06 2006-02-15 Байоджен Айдек Ма Інк. Спосіб лікування раку у ссавця за допомогою поліпептиду, що протидіє взаємодії april з його рецепторами
WO2001024812A1 (en) 1999-10-06 2001-04-12 N.V. Nutricia USE OF TRANSFORMING GROWTH FACTOR β AND GROWTH FACTORS IN THE TREATMENT AND PREVENTION OF DISEASES OF THE INTESTINAL MUCOSA
US20030012783A1 (en) 2001-02-20 2003-01-16 Wayne Kindsvogel Antibodies that bind both BCMA and TACI
GB0115256D0 (en) 2001-06-21 2001-08-15 Babraham Inst Mouse light chain locus
CA2499300A1 (en) 2002-10-31 2004-05-21 Genentech, Inc. Methods and compositions for increasing antibody production
US7575893B2 (en) 2003-01-23 2009-08-18 Genentech, Inc. Methods for producing humanized antibodies and improving yield of antibodies or antigen binding fragments in cell culture
EP3272770B1 (en) 2004-07-22 2023-12-20 Erasmus University Medical Center Rotterdam Method for the production of a vh heavy chain-only antibody in a transgenic mammal and binding polypeptide complex consisting of a dimer of a first chain and a second chain wherein each chain consists of two antigen-specific vh binding domains linked by a dimerisation domain
US20160355591A1 (en) 2011-05-02 2016-12-08 Immunomedics, Inc. Subcutaneous anti-hla-dr monoclonal antibody for treatment of hematologic malignancies
CA2720682A1 (en) 2008-04-25 2009-10-29 Zymogenetics, Inc. Levels of bcma protein expression on b cells and use in diagnostic methods
US20100122358A1 (en) 2008-06-06 2010-05-13 Crescendo Biologics Limited H-Chain-only antibodies
PT2406284T (pt) 2009-03-10 2016-09-29 Biogen Ma Inc Anticorpos anti-bcma
GB0905023D0 (en) 2009-03-24 2009-05-06 Univ Erasmus Medical Ct Binding molecules
US9345661B2 (en) 2009-07-31 2016-05-24 Genentech, Inc. Subcutaneous anti-HER2 antibody formulations and uses thereof
EP2640750A1 (en) 2010-11-16 2013-09-25 Boehringer Ingelheim International GmbH Agents and methods for treating diseases that correlate with bcma expression
US20130101599A1 (en) 2011-04-21 2013-04-25 Boehringer Ingelheim International Gmbh Bcma-based stratification and therapy for multiple myeloma patients
TWI679212B (zh) 2011-11-15 2019-12-11 美商安進股份有限公司 針對ｂｃｍａ之e3以及ｃｄ３的結合分子
US10077315B2 (en) 2013-02-05 2018-09-18 Engmab Sàrl Bispecific antibodies against CD3 and BCMA
EP2990416B1 (en) 2014-08-29 2018-06-20 GEMoaB Monoclonals GmbH Universal chimeric antigen receptor expressing immune cells for targeting of diverse multiple antigens and method of manufacturing the same and use of the same for treatment of cancer, infections and autoimmune disorders
JO3799B1 (ar) 2015-08-17 2021-01-31 Janssen Pharmaceutica Nv الأجسام المضادة ل bcma، جزيئات ربط الانتيجين ثنائية التحديد التي تربط bcma و cd3، و استخداماتها
BR112018076767A2 (pt) 2016-06-21 2019-04-02 Teneobio, Inc. anticorpos de ligação a cd3
CA3034706A1 (en) 2016-08-24 2018-03-01 Teneobio, Inc. Transgenic non-human animals producing modified heavy chain-only antibodies
WO2018052503A1 (en) 2016-09-14 2018-03-22 Teneobio, Inc. Cd3 binding antibodies
EP3634474A1 (en) 2017-06-09 2020-04-15 GEMoaB Monoclonals GmbH Targeting modules for universal chimeric antigen receptor expressing immune cells and use in the treatment of cancer infections and autoimmune disorders
CN117567624A (zh) * 2017-06-20 2024-02-20 特纳奥尼股份有限公司 仅有重链的抗bcma抗体
CA3067584A1 (en) * 2017-06-20 2018-12-27 Teneobio, Inc. Anti-bcma heavy chain-only antibodies
WO2019000223A1 (en) * 2017-06-27 2019-01-03 Nanjing Legend Biotech Co., Ltd. ENABLERS OF IMMUNE EFFECTOR CELLS OF CHIMERIC ANTIBODIES AND METHODS OF USE THEREOF
EP3645568B1 (en) 2017-06-30 2022-08-17 The U.S.A. as represented by the Secretary, Department of Health and Human Services Anti-b-cell maturation antigen chimeric antigen receptors with human domains

Also Published As

Publication number Publication date
MX2022016342A (es) 2023-01-24
JP2023532129A (ja) 2023-07-26
US20230257473A1 (en) 2023-08-17
WO2022006316A1 (en) 2022-01-06
CN116472049A (zh) 2023-07-21
CO2023000808A2 (es) 2023-02-16
BR112022027101A2 (pt) 2023-03-14
AU2021300179A1 (en) 2023-02-02
CL2022003754A1 (es) 2023-07-07
CR20220656A (es) 2023-03-01
EP4171750A1 (en) 2023-05-03
KR20230038211A (ko) 2023-03-17
CA3189297A1 (en) 2022-01-06
IL299027A (en) 2023-02-01

Similar Documents

Publication Publication Date Title
PE20230464A1 (es) Union de anticuerpos multiespecificos a bcma
CR20210326A (es) Moléculas agonistas de unión al antígeno cd28 que actúan sobre el tumor
PE20191208A1 (es) Anticuerpos anti-cd73 y usos de los mismos
CL2020003046A1 (es) Construcciones de anticuerpo biespecificos que se unen a dll3 y cd3 ( divisional de la solicitud 267-2018)
IL299221A (en) CD3 binding antibodies
PH12018501554A1 (en) Ror1 antibody compositions and related methods
PE20191131A1 (es) Anticuerpos anti antigeno 4 del linfocito t citotoxico (ctla-4) activables y sus usos
BR112019003775A2 (pt) anticorpo monoclonal anti-pd1, composição farmacêutica do mesmo e uso dos mesmos
PE20190970A1 (es) Anticuerpos anti-cd40 y sus usos
PE20231958A1 (es) Moleculas de union a pd-1 y metodos de uso de las mismas
BR112018011058A2 (pt) ?anticorpo, composição, método para tratamento de um indivíduo tendo um câncer, kit de partes, e, uso de um anticorpo ou composição?
PE20141017A1 (es) Anticuerpos del cea
PE20171654A1 (es) Composiciones y metodos usados para aumentar la respuesta inmune y en la terapia del cancer
BR112018005573A2 (pt) ?polipeptídeos de ligação a cd3?
AR078470A1 (es) Anticuerpos que se unen especificamente al receptor epha2
PE20141564A1 (es) Moleculas de union para bcma y cd3
MX2016012830A (es) Anticuerpos contra el receptor 2 del factor de crecimiento epidermico humano (her2) biespecificos.
PE20131209A1 (es) Anticuerpos anti-fap
AR087615A1 (es) Moleculas biespecificas de union a antigeno
PE20150025A1 (es) Anticuerpos e inmunoconjugados contra ly6e y metodos de uso
PE20090518A1 (es) Proteinas enlazantes de antigenos que enlazan al receptor de la interleucina 18 (il-18)
PE20170912A1 (es) Conjugados de anticuerpo-farmaco
PE20091342A1 (es) Inmunoglobulinas
PE20201171A1 (es) Anticuerpos de cadena pesada que se unen a cd22
EA202091590A1 (ru) Антитела против pd-l1 и варианты их применения